Literature DB >> 28187291

The Principles of Engineering Immune Cells to Treat Cancer.

Wendell A Lim1, Carl H June2.   

Abstract

Chimeric antigen receptor (CAR) T cells have proven that engineered immune cells can serve as a powerful new class of cancer therapeutics. Clinical experience has helped to define the major challenges that must be met to make engineered T cells a reliable, safe, and effective platform that can be deployed against a broad range of tumors. The emergence of synthetic biology approaches for cellular engineering is providing us with a broadly expanded set of tools for programming immune cells. We discuss how these tools could be used to design the next generation of smart T cell precision therapeutics.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28187291      PMCID： PMC5553442          DOI： 10.1016/j.cell.2017.01.016

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  148 in total

1.  Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27.

Authors:  Ruth D Fritsch; Xinglei Shen; Gary P Sims; Karen S Hathcock; Richard J Hodes; Peter E Lipsky
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

2.  Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Authors:  Evripidis Lanitis; Mathilde Poussin; Alex W Klattenhoff; Degang Song; Raphael Sandaltzopoulos; Carl H June; Daniel J Powell
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

3.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

4.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Authors:  Hollie J Pegram; James C Lee; Erik G Hayman; Gavin H Imperato; Thomas F Tedder; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

5.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

6.  Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy.

Authors:  David M Barrett; Nathan Singh; Xiaojun Liu; Shuguang Jiang; Carl H June; Stephan A Grupp; Yangbing Zhao
Journal:  Cytotherapy       Date:  2014-01-16       Impact factor: 5.414

7.  Prospects for gene-engineered T cell immunotherapy for solid cancers.

Authors:  Christopher A Klebanoff; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Med       Date:  2016-01       Impact factor: 53.440

8.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

9.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

10.  Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors.

Authors:  Leonardo Morsut; Kole T Roybal; Xin Xiong; Russell M Gordley; Scott M Coyle; Matthew Thomson; Wendell A Lim
Journal:  Cell       Date:  2016-01-28       Impact factor: 41.582
View more
  303 in total

Review 1.  Therapeutic targeting of trained immunity.

Authors:  Willem J M Mulder; Jordi Ochando; Leo A B Joosten; Zahi A Fayad; Mihai G Netea
Journal:  Nat Rev Drug Discov       Date:  2019-07       Impact factor: 84.694

2.  Functional TCR T cell screening using single-cell droplet microfluidics.

Authors:  Aude I Segaliny; Guideng Li; Lingshun Kong; Ci Ren; Xiaoming Chen; Jessica K Wang; David Baltimore; Guikai Wu; Weian Zhao
Journal:  Lab Chip       Date:  2018-12-04       Impact factor: 6.799

Review 3.  Advances in Biomaterials for Drug Delivery.

Authors:  Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer
Journal:  Adv Mater       Date:  2018-05-07       Impact factor: 30.849

4.  Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.

Authors:  Christopher A Pennell; Jessie L Barnum; Cameron S McDonald-Hyman; Angela Panoskaltsis-Mortari; Megan J Riddle; Zhengming Xiong; Michael Loschi; Govindarajan Thangavelu; Heather M Campbell; Meghan D Storlie; Yosef Refaeli; Scott N Furlan; Michael C Jensen; Leslie S Kean; Jeffrey S Miller; Jakub Tolar; Mark J Osborn; Bruce R Blazar
Journal:  Mol Ther       Date:  2018-04-07       Impact factor: 11.454

Review 5.  Delivery technologies for cancer immunotherapy.

Authors:  Rachel S Riley; Carl H June; Robert Langer; Michael J Mitchell
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

Review 6.  Versatile CAR T-cells for cancer immunotherapy.

Authors:  Fuliang Chu; Jingjing Cao; Sattva S Neelalpu
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

7.  Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.

Authors:  Aaron M Miller; Milad Bahmanof; Dietmar Zehn; Ezra E W Cohen; Stephen P Schoenberger
Journal:  Cancer Immunol Res       Date:  2018-11-27       Impact factor: 11.151

8.  Dissecting heterogeneous cell populations across drug and disease conditions with PopAlign.

Authors:  Sisi Chen; Paul Rivaud; Jong H Park; Tiffany Tsou; Emeric Charles; John R Haliburton; Flavia Pichiorri; Matt Thomson
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-30       Impact factor: 11.205

9.  p95HER2-T cell bispecific antibody for breast cancer treatment.

Authors:  Irene Rius Ruiz; Rocio Vicario; Beatriz Morancho; Cristina Bernadó Morales; Enrique J Arenas; Sylvia Herter; Anne Freimoser-Grundschober; Jitka Somandin; Johannes Sam; Oliver Ast; Águeda Martinez Barriocanal; Antonio Luque; Marta Escorihuela; Ismael Varela; Isabel Cuartas; Paolo Nuciforo; Roberta Fasani; Vicente Peg; Isabel Rubio; Javier Cortés; Violeta Serra; Santiago Escriva-de-Romani; Jeff Sperinde; Ahmed Chenna; Weidong Huang; John Winslow; Joan Albanell; Joan Seoane; Maurizio Scaltriti; Jose Baselga; Josep Tabernero; Pablo Umana; Marina Bacac; Cristina Saura; Christian Klein; Joaquín Arribas
Journal:  Sci Transl Med       Date:  2018-10-03       Impact factor: 17.956

Review 10.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.